55 research outputs found
Overview of the work carried out in CleanAtlantic on improving marine litter monitoring: • WP 5.2.1. – Improving methods for marine litter monitoring in the Atlantic Area: seabed, floating and coastal litter • WP 5.2.2. – New tools for the monitoring of marine litter
This report collates the main results delivered in the frame of the CleanAtlantic project, Work package 5.2.
Monitoring the presence of marine litter in the marine environment. With this purpose, an overview of new
and improved marine litter monitoring methods for seabed, water surface and coastal compartments in the
Atlantic Area is presented. Main findings, gaps on monitoring and research as well as potential
improvements and recommendations are highlighted. For some of the topics addressed partners produced fully-dedicated reports. In these cases, links to the original reports are included in the reference section for further information
Accuracy of colon capsule endoscopy in detecting colorectal polyps in individuals with familial colorectal cancer: could we avoid colonoscopies?
Background. Individuals with a family history of colorectal cancer (CRC) have an increased risk of CRC. We evaluated the diagnostic yield of CCE in the detection of lesions and also two different colon preparations. Methods. A prospective multicenter study was designed to assess CCE diagnostic yield in a cohort of asymptomatic individuals with a family history of CRC. CCE and colonoscopy were performed on the same day by 2 endoscopists who were blinded to the results of the other procedure. Results. Fifty-three participants were enrolled. The sensitivity, specificity, PPV, and NPV of CCE for detecting advanced adenomas were 100%, 98%, 67%, and 100%. Sensitivity, specificity, PPV, and NPV of CCE for the diagnosis of individuals with polyps were 87%, 97%, 93%, and 88%, respectively. CCE identify 100% of individuals with significant or advanced lesions. Overall cleanliness was adequate by 60.7% of them. The PEG-ascorbic boost seems to improve colon cleanliness, with similar colonic transit time. Conclusion. CCE is a promising tool, but it has to be considered as an alternative technique in this population in order to reduce the number of colonoscopies performed. More studies are needed to understand appropriate screening follow-up intervals and optimize the bowel preparation regimen
Colon capsule endoscopy versus CT colonography in FIT-positive colorectal cancer screening subjects: a prospective randomised trial-the VICOCA study
Background: Colon capsule endoscopy (CCE) and CT colonography (CTC) are minimally invasive techniques for colorectal cancer (CRC) screening. Our objective is to compare CCE and CTC for the identification of patients with colorectal neoplasia among participants in a CRC screening programme with positive faecal immunochemical test (FIT). Primary outcome was to compare the performance of CCE and CTC in detecting patients with neoplastic lesions. Methods: The VICOCA study is a prospective, single-centre, randomised trial conducted from March 2014 to May 2016; 662 individuals were invited and 349 were randomised to CCE or CTC before colonoscopy. Endoscopists were blinded to the results of CCE and CTC. Results: Three hundred forty-nine individuals were included: 173 in the CCE group and 176 in the CTC group. Two hundred ninety individuals agreed to participate: 147 in the CCE group and 143 in the CTC group. In the intention-toscreen analysis, sensitivity, specificity and positive and negative predictive values for the identification of individuals with colorectal neoplasia were 98.1%, 76.6%, 93.7% and 92.0% in the CCE group and 64.9%, 95.7%, 96.8% and 57.7% in the CTC group. In terms of detecting significant neoplastic lesions, the sensitivity of CCE and CTC was 96.1% and 79.3%, respectively. Detection rate for advanced colorectal neoplasm was higher in the CCE group than in the CTC group (100% and 93.1%, respectively; RR = 1.07; p = 0.08). Both CCE and CTC identified all patients with cancer. CCE detected more patients with any lesion than CTC (98.6% and 81.0%, respectively; RR = 1.22; p = 0.002). Conclusion: Although both techniques seem to be similar in detecting patients with advanced colorectal neoplasms, CCE is more sensitive for the detection of any neoplastic lesion
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Background: Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not been compared with that of chemotherapy in a phase III trial. Patients and methods: PEARL is a multicentre, phase III randomised study in which patients with aromatase inhibitor (AI)-resistant MBC were included in two consecutive cohorts. In cohort 1, patients were randomised 1 : 1 to palbociclib plus exemestane or capecitabine. On discovering new evidence about estrogen receptor-1 (ESR1) mutations inducing resistance to AIs, the trial was amended to include cohort 2, in which patients were randomised 1 : 1 between palbociclib plus fulvestrant and capecitabine. The stratification criteria were disease site, prior sensitivity to ET, prior chemotherapy for MBC, and country of origin. Co-primary endpoints were progression-free survival (PFS) in cohort 2 and in wild-type ESR1 patients (cohort 1 + cohort 2). ESR1 hotspot mutations were analysed in baseline circulating tumour DNA. Results: From March 2014 to July 2018, 296 and 305 patients were included in cohort 1 and cohort 2, respectively. Palbociclib plus ET was not superior to capecitabine in both cohort 2 [median PFS: 7.5 versus 10.0 months; adjusted hazard ratio (aHR): 1.13; 95% confidence interval (CI): 0.85-1.50] and wild-type ESR1 patients (median PFS: 8.0 versus 10.6 months; aHR: 1.11; 95% CI: 0.87-1.41). The most frequent grade 3-4 toxicities with palbociclib plus exemestane, palbociclib plus fulvestrant and capecitabine, respectively, were neutropenia (57.4%, 55.7% and 5.5%), hand/foot syndrome (0%, 0% and 23.5%), and diarrhoea (1.3%, 1.3% and 7.6%). Palbociclib plus ET offered better quality of life (aHR for time to deterioration of global health status: 0.67; 95% CI: 0.53-0.85). Conclusions: There was no statistical superiority of palbociclib plus ET over capecitabine with respect to PFS in MBC patients resistant to AIs. Palbociclib plus ET showed a better safety profile and improved quality of life
Evaluation of different bowel preparations for small bowel capsule endoscopy: a prospective, randomized, controlled study
To obtain an adequate view of the whole small
intestine during capsule endoscopy (CE) a clear liquid diet and overnight fasting
is recommended. However, intestinal content can hamper vision in spite of these
measures. Our aim was to evaluate tolerance and degree of intestinal cleanliness
during CE following three types of bowel preparation. PATIENTS AND METHODS: This
was a prospective, multicenter, randomized, controlled study. Two-hundred
ninety-one patients underwent one of the following preparations: 4 L of clear
liquids (CL) (group A; 92 patients); 90 mL of aqueous sodium phosphate (group B;
89 patients); or 4 L of a polyethylene glycol electrolyte solution (group C; 92
patients). The degree of cleanliness of the small bowel was classified by blinded
examiners according to four categories (excellent, good, fair or poor). The
degree of patient satisfaction, gastric and small bowel transit times, and
diagnostic yield were measured. RESULTS: The degree of cleanliness did not differ
significantly between the groups (P = 0.496). Interobserver concordance was fair
(k = 0.38). No significant differences were detected between the diagnostic
yields of the CE (P = 0.601). Gastric transit time was 35.7 +/- 3.7 min (group
A), 46.1 +/- 8.6 min (group B) and 34.6 +/- 5.0 min (group C) (P = 0.417).
Small-intestinal transit time was 276.9 +/- 10.7 min (group A), 249.7 +/- 13.1
min (group B) and 245.6 +/- 11.6 min (group C) (P = 0.120). CL was the best
tolerated preparation. Compliance with the bowel preparation regimen was lowest
in group C (P = 0.008). CONCLUSIONS: A clear liquid diet and overnight fasting is
sufficient to achieve an adequate level of cleanliness and is better tolerated by
patients than other forms of preparation
The Near Infrared Imager and Slitless Spectrograph for the James Webb Space Telescope -- IV. Aperture Masking Interferometry
The James Webb Space Telescope's Near Infrared Imager and Slitless
Spectrograph (JWST-NIRISS) flies a 7-hole non-redundant mask (NRM), the first
such interferometer in space, operating at 3-5 \micron~wavelengths, and a
bright limit of magnitudes in W2. We describe the NIRISS Aperture
Masking Interferometry (AMI) mode to help potential observers understand its
underlying principles, present some sample science cases, explain its
operational observing strategies, indicate how AMI proposals can be developed
with data simulations, and how AMI data can be analyzed. We also present key
results from commissioning AMI. Since the allied Kernel Phase Imaging (KPI)
technique benefits from AMI operational strategies, we also cover NIRISS KPI
methods and analysis techniques, including a new user-friendly KPI pipeline.
The NIRISS KPI bright limit is W2 magnitudes. AMI (and KPI) achieve
an inner working angle of mas that is well inside the mas
NIRCam inner working angle for its circular occulter coronagraphs at comparable
wavelengths.Comment: 30 pages, 10 figure
A window to the sea: environmental indicators for coastal risk management under the RAIA observatory (NW-Iberian Peninsula)
Poster.-- International Ocean Data Conference 2022, Sopot, Poland, 14-16 February 2022Environmental indicators are fundamental tools for the evaluation and mitigation of environmental risks, showing the current state and helping to predict future changes on ecosystem health regarding environmental risks The framework of the RAIA observatory www marnaraia org identified 38 environmental indicators, in which 12 key risks affecting the ecosystem services of the Euroregion Galicia Northern Portugal have been evaluated The objective of this initiative is to optimize and analyze the environmental indicators identified for the Euroregion and make them available through a Web service that allows users to get information on the current state and evolution of the ecosystem healthThis contribution has been funded by the European Union MarRISK project Adaptación costera ante el Cambio Climático conocer los riesgos y aumentar la resiliencia (0262_MarRISK1_E) through EP-INTERREG V A España-Portugal (POCTEP) programN
The James Webb Space Telescope Mission: Optical Telescope Element Design, Development, and Performance
The James Webb Space Telescope (JWST) is a large, infrared space telescope
that has recently started its science program which will enable breakthroughs
in astrophysics and planetary science. Notably, JWST will provide the very
first observations of the earliest luminous objects in the Universe and start a
new era of exoplanet atmospheric characterization. This transformative science
is enabled by a 6.6 m telescope that is passively cooled with a 5-layer
sunshield. The primary mirror is comprised of 18 controllable, low areal
density hexagonal segments, that were aligned and phased relative to each other
in orbit using innovative image-based wavefront sensing and control algorithms.
This revolutionary telescope took more than two decades to develop with a
widely distributed team across engineering disciplines. We present an overview
of the telescope requirements, architecture, development, superb on-orbit
performance, and lessons learned. JWST successfully demonstrates a segmented
aperture space telescope and establishes a path to building even larger space
telescopes.Comment: accepted by PASP for JWST Overview Special Issue; 34 pages, 25
figure
Role of age and comorbidities in mortality of patients with infective endocarditis
[Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality.
[Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk.
[Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality.
[Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients
Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when = 50 years and symptomatic for <= 7days were included. The intervention consisted of 200-300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo; they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311); OR for hospitalization or death was 0.919 (CI 0.592-1.416). CP effect on hospital admission or death was largest in patients with <= 5 days of symptoms (OR 0.658, 95%CI 0.394-1.085). CP did not decrease the time to full symptom resolution
- …